178 related articles for article (PubMed ID: 25720079)
1. INR vs. thrombin generation assays for guiding VKA reversal: a retrospective comparison.
Herpers R; van Rossum AP; van Beem RT; Michel WM; Strijbis VJ; Strengers PF; Castel A; Brinkman HJ
Clin Chem Lab Med; 2015 Jul; 53(8):1227-36. PubMed ID: 25720079
[TBL] [Abstract][Full Text] [Related]
2. A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment.
Riva N; Vella K; Meli S; Hickey K; Zammit D; Calamatta C; Makris M; Kitchen S; Ageno W; Gatt A
Int J Lab Hematol; 2017 Oct; 39(5):482-488. PubMed ID: 28500649
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.
Desmettre T; Dehours E; Samama CM; Jhundoo S; Pujeau F; Guillaudin C; Hecquart C; Clerson P; Crave JC; Jaussaud R
Crit Care; 2012 Oct; 16(5):R185. PubMed ID: 23036234
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
Gerotziafas GT; Dupont C; Spyropoulos AC; Hatmi M; Samama MM; Kiskinis D; Elalamy I
Thromb Haemost; 2009 Jul; 102(1):42-8. PubMed ID: 19572066
[TBL] [Abstract][Full Text] [Related]
5. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays.
Choi Q; Kim JE; Hyun J; Han KS; Kim HK
Thromb Res; 2013 Jul; 132(1):e70-5. PubMed ID: 23769659
[TBL] [Abstract][Full Text] [Related]
6. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
Tanaka KA; Szlam F; Dickneite G; Levy JH
Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
[TBL] [Abstract][Full Text] [Related]
7. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy.
Khorsand N; Veeger NJ; Muller M; Overdiek JW; Huisman W; van Hest RM; Meijer K
Transfus Med; 2011 Apr; 21(2):116-23. PubMed ID: 21073580
[TBL] [Abstract][Full Text] [Related]
8. Thrombin generation and international normalized ratio in inherited thrombophilia patients receiving thromboprophylactic therapy.
Luna-Záizar H; González-Moncada AI; Padilla-López EL; Ramírez-Anguiano AC; Pacheco-Moisés FP; Velasco-Ramírez SF; Padilla-Romo MG; Borjas-Gutierrez C; Jaloma-Cruz AR
Thromb Res; 2015 Dec; 136(6):1291-8. PubMed ID: 26493603
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.
Khorsand N; Kooistra HA; van Hest RM; Veeger NJ; Meijer K
Thromb Res; 2015 Jan; 135(1):9-19. PubMed ID: 25480313
[TBL] [Abstract][Full Text] [Related]
10. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
[TBL] [Abstract][Full Text] [Related]
11. Laboratory assessment of warfarin reversal with global coagulation tests versus international normalized ratio in patients with intracranial bleeding.
Voils SA; Martin EJ; Mohammed BM; Bayrlee A; Brophy DF
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):443-7. PubMed ID: 25699612
[TBL] [Abstract][Full Text] [Related]
12. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.
Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K
Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728
[TBL] [Abstract][Full Text] [Related]
13. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
[TBL] [Abstract][Full Text] [Related]
14. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
15. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal.
Altorjay Á; Szabó É; Boda Z; Kramer L; Ngo LY; Engl W; Firth CL; Ahlstrom ER; Gelmont DM; Pabinger I
Thromb Res; 2015 Mar; 135(3):485-91. PubMed ID: 25613927
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates.
Spiezia L; Rossetto V; Campello E; Bulato C; Radu CM; Simioni P
Blood Coagul Fibrinolysis; 2020 Mar; 31(2):127-131. PubMed ID: 31934885
[TBL] [Abstract][Full Text] [Related]
17. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
Yasaka M; Sakata T; Naritomi H; Minematsu K
Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
[TBL] [Abstract][Full Text] [Related]
18. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
19. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal.
Baggs JH; Patanwala AE; Williams EM; Erstad BL
Ann Pharmacother; 2012 Jan; 46(1):51-6. PubMed ID: 22190253
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
